Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.40 |
| ▸ | TTL | Q8NG68 | 5/20 | 0.38 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Scoparic Acid A SCHEMBL31051329 | 1.00 | MAPT (0.42) | MAPTMEN1LMNATP53CYP3A4 | |
| Scoparic Acid A SCHEMBL30621453 | 1.00 | MAPT (0.42) | MAPTMEN1LMNATP53CYP3A4 | |
| Scopadiol SCHEMBL16610408 | 0.90 | TTL (0.44) | MAPTMEN1LMNATP53CYP3A4 | |
| Scoparic Acid B SCHEMBL30621452 | 0.89 | MAPT (0.43) | MAPTMEN1LMNATP53CYP3A4 | |
| Scoparic Acid B SCHEMBL14554122 | 0.89 | MAPT (0.43) | MAPTMEN1LMNATP53CYP3A4 | |
| Scoparic Acid C SCHEMBL30621454 | 0.86 | MAPT (0.41) | MAPTMEN1LMNATP53CYP3A4 | |
| Scoparic Acid C SCHEMBL16610413 | 0.86 | MAPT (0.41) | MAPTMEN1LMNATP53CYP3A4 | |
| SCHEMBL31051333 | 0.81 | TTL (0.43) | MAPTMEN1LMNATP53CYP3A4 | |
| SCHEMBL14552920 | 0.78 | TP53 (0.43) | MAPTMEN1LMNATP53CYP3A4 | |
| SCHEMBL16606704 | 0.78 | TP53 (0.43) | MAPTMEN1LMNATP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150093371-A1 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE | Humanitas Technology, LLC (US) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150093371-A1 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE | DDX5, MAVS, EIF2AK2 | MAPT 4177/4885MEN1 4698/4885LMNA 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.